The Experts below are selected from a list of 339 Experts worldwide ranked by ideXlab platform
Robert Krause - One of the best experts on this subject based on the ideXlab platform.
-
first report of nocardia asiatica Olecranon Bursitis in an immunocompetent traveler returning to austria
Journal of Clinical Microbiology, 2013Co-Authors: Eva Leitner, Thomas Valentin, Martin Hoenigl, Philipp Lanz, Holger Flick, Ines Zollnerschwetz, Andrea J Grisold, Gebhard Feierl, Robert KrauseAbstract:Nocardia spp. are rarely isolated in extrapulmonary clinical specimens. We describe the first case of Olecranon Bursitis caused by Nocardia asiatica. The patient, a traveler returning from Thailand, was successfully treated with linezolid.
Anthony P Cannella - One of the best experts on this subject based on the ideXlab platform.
-
case report Olecranon Bursitis due to prototheca wickerhamii in an immunocompromised patient
American Journal of Tropical Medicine and Hygiene, 2019Co-Authors: Kruti Yagnik, Raphael C Bosse, Jennifer Reppucci, Rachel Butts, Shehla Islam, Anthony P CannellaAbstract:: Human protothecosis is a rare algal infection caused by Prototheca; it is a ubiquitous achlorophyllic alga, which rarely causes human disease. Currently, the pathogenesis remains unclear and no treatment options have been elucidated. We present a case of Olecranon Bursitis caused by Prototheca wickerhamii in an immunocompromised patient. A 45-year-old man presented with left elbow pain after scraping his elbow on a tree. He reported significant pain and swelling of the elbow after injury, which resolved without intervention. He was diagnosed with HIV/AIDS infection and started on antiretroviral therapy. Afterward, he experienced recurrent elbow swelling and pain; an incision and drainage was performed and cultures demonstrated P. wickerhamii. Unsuccessful treatment with oral voriconazole led to an attempt at therapy with parental amphotericin and oral doxycycline; however the patient left against medical advice. He presented to our facility and both parental amphotericin and doxycycline were initiated with planned outpatient bursectomy. He clinically improved on that regimen but left against medical advice before completing his recommended course of IV amphotericin and oral doxycycline. Patients diagnosed with disseminated protothecosis can have a mortality rate upward of 67%. Given the rarity of this pathogen, no official treatment guidelines exist and there are few studies analyzing the antimicrobial susceptibility of Prototheca. Management is challenging because of slow-growing nature of the algae, paucity of research studies, and limited susceptibility of this pathogen. This case adds to the limited body of literature by demonstrating the clinical presentation of protothecosis and highlighting the pathology and current treatment options.
Bernard F Morrey - One of the best experts on this subject based on the ideXlab platform.
-
surgical treatment of aseptic Olecranon Bursitis
Journal of Shoulder and Elbow Surgery, 1997Co-Authors: Nathaniel J Stewart, James B Manzanares, Bernard F MorreyAbstract:Most cases of aseptic Olecranon Bursitis respond to conservative treatment, yet some will develop a chronic Bursitis with sufficient symptoms to warrant surgery. Over a 10-year period 21 cases of aseptic Olecranon Bursitis were treated surgically at our institution. Surveillance was a minimum of 2 years and averaged 5.2 years. The procedure provided complete and long-term relief in only 40% (two of five) of patients with rheumatoid arthritis, whereas 94% (15 of 16) of the patients without rheumatoid arthritis did well (p = 0.028, Fisher's Exact test). No patients had deep infection or draining wounds. Properly performed surgical treatment of aseptic Olecranon Bursitis appears to offer long-lasting symptomatic relief to patients without rheumatoid arthritis.
Didier Pittet - One of the best experts on this subject based on the ideXlab platform.
-
one vs 2 stage bursectomy for septic Olecranon and prepatellar Bursitis a prospective randomized trial
Mayo Clinic proceedings, 2017Co-Authors: Ilker Uckay, Elodie Von Dach, Cedric Perez, Americo Agostinho, Philippe Garnerin, Benjamin A Lipsky, Pierre Hoffmeyer, Didier PittetAbstract:Abstract Objective To assess the optimal surgical approach and costs for patients hospitalized with septic Bursitis. Patients and Methods From May 1, 2011, through December 24, 2014, hospitalized patients with septic Bursitis at University of Geneva Hospitals were randomized (1:1) to receive 1- vs 2-stage bursectomy. All the patients received postsurgical oral antibiotic drug therapy for 7 days. Results Of 164 enrolled patients, 130 had Bursitis of the elbow and 34 of the patella. The surgical approach used was 1-stage in 79 patients and 2-stage in 85. Overall, there were 22 treatment failures: 8 of 79 patients (10%) in the 1-stage arm and 14 of 85 (16%) in the 2-stage arm (Pearson χ 2 test; P =.23). Recurrent infection was caused by the same pathogen in 7 patients (4%) and by a different pathogen in 5 (3%). Outcomes were better in the 1- vs 2-stage arm for wound dehiscence for elbow Bursitis (1 of 66 vs 9 of 64; Fisher exact test P =.03), median length of hospital stay (4.5 vs 6.0 days), nurses' workload (605 vs 1055 points), and total costs (Sw₣6881 vs Sw₣11,178; all P Conclusion For adults with moderate to severe septic Bursitis requiring hospital admission, bursectomy with primary closure, together with antibiotic drug therapy for 7 days, was safe, effective, and resource saving. Using a 2-stage approach may be associated with a higher rate of wound dehiscence for Olecranon Bursitis than the 1-stage approach. Trial Registration Clinicaltrials.gov Identifier: NCT01406652.
Jennifer Moriatis Wolf - One of the best experts on this subject based on the ideXlab platform.
-
clinical management of Olecranon Bursitis a review
Journal of Hand Surgery (European Volume), 2021Co-Authors: Nzuekoh Nchinda, Jennifer Moriatis WolfAbstract:Olecranon Bursitis is a disease characterized by inflammation of the Olecranon bursa, most often due to microtrauma. Although it is a common condition, there is a lack of evidence-based recommendations for the management of nonseptic Olecranon Bursitis. The condition is often self-limited and resolves with conservative methods such as rest, ice, compression, orthosis wear, and nonsteroidal anti-inflammatory medications. Older studies have shown resolution of symptoms with intrabursal corticosteroid injections and surgical bursectomy. More recent literature has demonstrated adverse effects of intrabursal injections and surgery compared with noninvasive management for initial treatment of nonseptic Olecranon Bursitis. In order to better tailor decision-making, it is important that hand surgeons understand the comparative efficacies of each option for management of nonseptic Olecranon Bursitis.
